Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline.

@article{Bolchoz2001PrimaquineinducedHA,
  title={Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline.},
  author={Laura J C Bolchoz and Robert A. Budinsky and D C Mcmillan and David J. Jollow},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2001},
  volume={297 2},
  pages={
          509-15
        }
}
Primaquine is an important antimalarial agent because of its activity against exoerythrocytic forms of Plasmodium spp. However, methemoglobinemia and hemolytic anemia are dose-limiting side effects of primaquine therapy that limit its efficacy. These hemotoxicities are thought to be mediated by metabolites; however, the identity of the toxic species has remained unclear. Since N-hydroxy metabolites are known to mediate the hemotoxicity of several arylamines, the present studies were undertaken… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 30 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Ethnic variation and genetic susceptibility : glucose - 6 - phosphate dehydrogenase deficiency , in Biomarkers

DJ Jollow, DC McMillan
  • Medical and Workplace Applications
  • 1998
VIEW 1 EXCERPT